Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology company focused on developing universally implantable, bioengineered human tissues, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at the Nasdaq World Headquarters in New York on May 20, 2025.
The company's Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will participate in a fireside chat at 12:30 p.m. EST. Management will also be available for one-on-one meetings. A webcast replay will be accessible through the Events & Presentations section of Humacyte's website.
Humacyte (NASDAQ: HUMA), a clinical-stage biotechnology company focused on developing universally implantable, bioengineered human tissue, has scheduled its Q1 2025 financial results release and corporate update for May 13, 2025. The company will host a conference call and webcast at 8:30 AM ET.
U.S. investors can join via 1-877-704-4453, while international participants can dial 1-201-389-0920 using conference ID 13753487. The webcast will be available 15 minutes before the call and remain accessible on the company's investor relations website for at least 30 days afterward.
Humacyte (NASDAQ: HUMA) announced its Q4 and full-year 2024 financial results, highlighting the FDA approval of Symvess™ for extremity vascular trauma treatment in December 2024. The company has initiated commercial launch with first sales in February 2025, with 34 hospitals starting the Value Analysis Committee approval process and three hospitals already approving purchases.
Financial highlights show no revenue for Q4 and full-year 2024. R&D expenses were $20.7M in Q4 2024 and $88.6M for the full year. Net loss increased to $148.7M for 2024, compared to $110.8M in 2023. The company reported $95.3M in cash and equivalents as of December 31, 2024, with an additional $46.6M raised through a public offering in March 2025.
Key developments include positive Phase 3 trial results for arteriovenous access in dialysis patients, plans for a supplemental BLA submission in H2 2026, and an upcoming IND filing in 2025 for coronary artery bypass grafting studies.
Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissue at commercial scale, has scheduled its Q4 and full-year 2024 financial results release for March 28, 2025.
The company will host a webcast and conference call at 8:30 a.m. ET on the same day. The webcast will be available 15 minutes before the call begins, and a replay will be accessible on the company's investor relations website for at least 30 days following the broadcast.
Humacyte (Nasdaq: HUMA) has announced the pricing of a public offering of 25,000,000 shares of common stock at $2.00 per share, expecting to raise gross proceeds of $50 million. The offering is set to close around March 27, 2025.
The company has granted underwriters a 30-day option to purchase up to an additional 3,750,000 shares. TD Cowen, Barclays, and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company are acting as lead managers.
The net proceeds will be used to fund the commercialization of SYMVESS™ in vascular trauma indication, development of product candidates in Humacyte's pipeline, and for working capital and general corporate purposes.
Humacyte (Nasdaq: HUMA) has announced an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase up to an additional 15% of offered shares. TD Cowen, Barclays, and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company act as lead managers.
The commercial-stage biotechnology platform company, focused on developing universally implantable bioengineered human tissues, intends to use the proceeds to fund:
- Commercialization of SYMVESS™ in vascular trauma indication
- Development of product candidates in pipeline
- Working capital and general corporate purposes
The offering will be made through a shelf registration statement previously filed and declared effective by the SEC. The final size, terms, and completion of the offering remain subject to market conditions.
Humacyte (Nasdaq: HUMA) announced the publication of a Budget Impact Model (BIM) for Symvess in the Journal of Medical Economics. Symvess, a bioengineered human tissue for vascular repair, received FDA approval on December 19, 2024.
The economic analysis reveals significant cost savings for both trauma centers and payers. For trauma centers, the average per-patient cost with Symvess is $121,615 (including $29,500 purchase price), compared to $154,722 for cryopreserved allograft, $140,428 for bovine xenograft, and $137,213 for prosthetic grafts. For commercial payers, Symvess costs $94,165 per patient versus $181,127 for prosthetic grafts.
Cost savings are primarily attributed to reduced rates of vascular conduit infection and amputation. The model incorporated data from the PROOVIT registry, hospital charges, insurance claims, and expert opinion.
Trestle Biotherapeutics and Humacyte (Nasdaq: HUMA) have announced a research collaboration to explore technology synergies for bioengineering vascularized organs for transplantation. The partnership will investigate the integration of Trestle Bio's biofabricated human kidney tissues with Humacyte's FDA-approved ATEV™ technology.
The collaboration aims to develop a human bioengineered kidney with vascular perfusion, targeting the significant global need in kidney disease treatment. Currently, over 800 million patients worldwide suffer from chronic kidney disease, with 600,000 US patients dependent on dialysis. While approximately 100,000 patients are on the transplant waiting list, only 25,000 successful transplants occur annually.
Trestle Bio's technology focuses on developing implantable bioengineered kidney tissue designed to reduce ESRD patients' dialysis dependency. This collaboration follows Humacyte's recent FDA approval for ATEV™ as a vascular conduit for extremity arterial injury treatment.
Humacyte (Nasdaq: HUMA) has announced an upcoming investor event, scheduled for March 6, 2025, at 12:00 PM ET in New York, available both in-person and virtually. The event will spotlight Symvess, their groundbreaking bioengineered human tissue product that received FDA approval in December 2024.
The presentation will feature vascular surgery experts Dr. Michael Curi from Rutgers New Jersey Medical School and Dr. Sammy Siada from UCSF Fresno, alongside company management. They will discuss commercial strategies and initial market performance of Symvess, a first-in-class universally implantable vascular conduit.
The FDA approved Symvess for adult use in extremity arterial injury cases requiring urgent revascularization to prevent limb loss, specifically when autologous vein grafts aren't viable. The event will conclude with a Q&A session, and a webcast replay will be available on Humacyte's investor relations website.